Rigel Pharmaceuticals (RIGL) Interest & Investment Income (2010 - 2026)
Rigel Pharmaceuticals' quarterly Interest & Investment Income came in at $1.2 million in Q1 2026, up 103.89% year-on-year from $591000.0 in Q1 2025, and down 3.06% quarter-over-quarter from $1.2 million in Q4 2025.
Rigel Pharmaceuticals has reported Interest & Investment Income for 17 years, with the latest figure at $1.2 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 103.89% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 105.5% YoY), and the FY2025 full-year result was $3.7 million, up 75.96% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $1.2 million, down from $1.2 million in the prior quarter.
- The five-year high for Interest & Investment Income was $1.2 million in Q4 2025, with the low at $21000.0 in Q1 2022.
- Average Interest & Investment Income over 5 years is $584352.9, with a median of $552000.0 recorded in 2024.
- Year-over-year, Interest & Investment Income soared 2581.25% in 2022 and sank 36.76% in 2024.
- Tracing RIGL's Interest & Investment Income over 5 years: stood at $429000.0 in 2022, then soared by 58.04% to $678000.0 in 2023, then declined by 23.01% to $522000.0 in 2024, then soared by 138.12% to $1.2 million in 2025, then declined by 3.06% to $1.2 million in 2026.
- The last three Interest & Investment Income figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.21 Mn |
| Dec 31, 2025 | 1.24 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 753,000.00 |
| Mar 31, 2025 | 591,000.00 |
| Dec 31, 2024 | 522,000.00 |
| Sep 30, 2024 | 425,000.00 |
| Jun 30, 2024 | 552,000.00 |
| Mar 31, 2024 | 593,000.00 |
| Dec 31, 2023 | 678,000.00 |
| Sep 30, 2023 | 672,000.00 |
| Jun 30, 2023 | 529,000.00 |
| Mar 31, 2023 | 393,000.00 |
| Dec 31, 2022 | 429,000.00 |
| Sep 30, 2022 | 192,000.00 |
| Jun 30, 2022 | 42,000.00 |
| Mar 31, 2022 | 21,000.00 |
| Dec 31, 2021 | 16,000.00 |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | 16,000.00 |
| Mar 31, 2021 | 1,000.00 |
| Dec 31, 2020 | 19,000.00 |
| Sep 30, 2020 | 36,000.00 |
| Jun 30, 2020 | 169,000.00 |
| Mar 31, 2020 | 358,000.00 |
| Dec 31, 2019 | 464,000.00 |
| Sep 30, 2019 | 555,000.00 |
| Jun 30, 2019 | 733,000.00 |
| Mar 31, 2019 | 780,000.00 |
| Dec 31, 2018 | 696,000.00 |
| Sep 30, 2018 | 604,000.00 |
| Jun 30, 2018 | 554,000.00 |
| Mar 31, 2018 | 349,000.00 |
| Dec 31, 2017 | 344,000.00 |
| Sep 30, 2017 | 195,000.00 |
| Jun 30, 2017 | 197,000.00 |
| Mar 31, 2017 | 156,000.00 |
| Dec 31, 2016 | 109,000.00 |
| Sep 30, 2016 | 110,000.00 |
| Jun 30, 2016 | 115,000.00 |
| Mar 31, 2016 | 103,000.00 |
| Dec 31, 2015 | 60,000.00 |
| Sep 30, 2015 | 54,000.00 |
| Jun 30, 2015 | 62,000.00 |
| Mar 31, 2015 | 48,000.00 |
| Dec 31, 2014 | 44,000.00 |
| Sep 30, 2014 | 54,000.00 |
| Jun 30, 2014 | 65,000.00 |
| Mar 31, 2014 | 82,000.00 |
| Dec 31, 2013 | 67,000.00 |
| Sep 30, 2013 | 106,000.00 |
| Jun 30, 2013 | 117,000.00 |
| Mar 31, 2013 | 136,000.00 |
| Dec 31, 2012 | 127,000.00 |
| Sep 30, 2012 | 113,000.00 |
| Jun 30, 2012 | 144,000.00 |
| Mar 31, 2012 | 136,000.00 |
| Dec 31, 2011 | 126,000.00 |
| Sep 30, 2011 | 114,000.00 |
| Jun 30, 2011 | 90,000.00 |
| Mar 31, 2011 | 90,000.00 |
| Dec 31, 2010 | 90,000.00 |
| Sep 30, 2010 | 90,000.00 |
| Jun 30, 2010 | 76,000.00 |